Search Results - "Boudraa, Y."

A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer by Paridaens, R., Van Aelst, F., Georgoulias, V., Samonnig, H., Cocquyt, V., Zielinski, C., Hausmaninger, H., Willemse, P., Boudraa, Y., Wildiers, J., Ramazeilles, C., Azli, N.

“…Background: This phase II study evaluated the feasibility and efficacy of alternating and sequential regimens of docetaxel and doxorubicin as first-line…”
Get full text

Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial by Bang, Yung-Jue, Kang, Won Ki, Kang, Yoon-Koo, Kim, Hugh Chul, Jacques, Christian, Zuber, Emmanuel, Daglish, Byzance, Boudraa, Yvane, Kim, Won Seog, Heo, Dae Seog, Kim, Noe Kyeong

“…The aim of the present study was to confirm the efficacy and tolerability of docetaxel 75 mg/m(2) in a population of Korean patients with advanced gastric…”
Get full text

A phase II randomized study of doxorubicin (A) alternated to docetaxel (T) (ALT) vs sequential administration of 4 cy of t followed by 4 cy of a (seq) as 1st line ct in mbc pts by Paridaens, R., Van Aelst, F., Georgoulias, G., Samonnig, H., Van Belle, S., Zielinsky, C., Hausmaninger, H., Willemse, P., Boudraa, Y., Azli, N.

Get full text